Screener
Gilead Sciences GILD Yescarta — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000882095-26-000031
| (in millions) | Three Months Ended June 30, 2026 / U.S. | Three Months Ended June 30, 2026 / Europe | Three Months Ended June 30, 2026 / Rest of World | Three Months Ended June 30, 2026 / Total | Three Months Ended June 30, 2025 / U.S. | Three Months Ended June 30, 2025 / Europe | Three Months Ended June 30, 2025 / Rest of World | Three Months Ended June 30, 2025 / Total |
|---|---|---|---|---|---|---|---|---|
| Oncology | ||||||||
| Cell Therapy | ||||||||
| Tecartus | 29 | 34 | 8 | 70 | 41 | 41 | 9 | 92 |
| Yescarta | 132 | 139 | 75 | 346 | 162 | 154 | 77 | 393 |
| Total Cell Therapy | 161 | 173 | 83 | 417 | 203 | 196 | 86 | 485 |
| Trodelvy | 307 | 92 | 57 | 457 | 224 | 96 | 44 | 364 |
| Total Oncology | 468 | 265 | 140 | 873 | 427 | 291 | 131 | 849 |
| Other |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Gilead Sciences's yescarta — total revenues?
- Gilead Sciences (GILD) reported yescarta — total revenues of $346M in Q2 2026.
- How has Gilead Sciences's yescarta — total revenues changed year-over-year?
- Gilead Sciences's yescarta — total revenues decreased by 12.0% year-over-year, from $393M to $346M.
- What is the long-term trend for Gilead Sciences's yescarta — total revenues?
- Over 4 years (2021 to 2025), Gilead Sciences's yescarta — total revenues has grown at a 21.1% compound annual growth rate (CAGR), from $695M to $1.5B.
- What does yescarta — total revenues mean?
- This metric represents the total gross sales generated from the specific cell therapy product line within the company's oncology portfolio. It reflects the market adoption and commercial performance of chimeric antigen receptor T-cell (CAR-T) therapies used in the treatment of hematologic malignancies. Tracking this revenue stream provides insight into the company's competitive position in the high-growth cell therapy market and the success of its oncology commercialization strategy.
Ask your AI about Gilead Sciences's yescarta — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude